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ABSTRACT
Objective To assess the impact of prophylactic oral co-
trimoxazole in reducing mortality in HIV positive Zambian
adults being treated for pulmonary tuberculosis.
Design Double blind placebo controlled randomised
clinical trial.
Participants Two groups of antiretroviral treatment naive
adults with HIV infection: patients newly diagnosed as
having tuberculosis and receiving tuberculosis treatment
either for the first time or for retreatment after relapse;
previously treated patients not receiving treatment.
Intervention Oral co-trimoxazole or matching placebo
daily.
PrimaryoutcomemeasuresTimetodeathandoccurrence
of serious adverse events related to study drug.
Results 1003 patients were randomised: 835 (416 co-
trimoxazole, 419 placebo) were receiving treatment for
tuberculosis, 762 (376 co-trimoxazole, 386 placebo) of
them newly diagnosed previously untreated patients and
73 (40 co-trimoxazole, 33 placebo) receiving a
retreatmentregimen;168(84co-trimoxazole,84placebo)
were not on treatment but had received treatment in the
past. Of 835 participants receiving tuberculosis
treatment, follow-up information was available for 757,
witha totalof 1012.6 personyears offollow-up. A totalof
310(147co-trimoxazole,163placebo)participantsdied,
corresponding to death rates of 27.3 and 34.4 per 100
person years. In the Cox regression analysis, the hazard
ratio for death (co-trimoxazole:placebo) was 0.79 (95%
confidence interval 0.63 to 0.99). The effect of co-
trimoxazole waned with time, possibly owing to falling
adherence levels; in a per protocol analysis based on
patients who spent at least 90% of their time at risk
suppliedwith study drug,the hazard ratiowas 0.65(0.45
to 0.93).
Conclusions Prophylaxis with co-trimoxazole reduces
mortality in HIV infected adults with pulmonary
tuberculosis. Co-trimoxazole was generally safe and well
tolerated.
Trial registration Current Controlled Trials
ISRCTN15281875.
INTRODUCTION
Tuberculosisand HIVare leadingcausesof morbidity
andmortalityinsub-SaharanAfrica.Zambiahasoneof
the highest case notification rates of tuberculosis in the
world(700per100000),andahighproportion(70%)of
people with active tuberculosis are co-infected with
HIV.
1 Despite the availability of effective anti-
tuberculosis chemotherapy, mortality in HIV positive
people with tuberculosis remains high. Increasing
evidenceindicatesthatthisisprobablyduetobacterial
sepsis.
23Ratesofbacterialpneumoniaareseveraltimes
higher among HIV positive adults than in the general
community.
In 1999 a randomised placebo controlled clinical
trial in HIV positive patients with sputum smear
positive pulmonary tuberculosis in Côte d’Ivoire
found that co-trimoxazole prophylaxis significantly
reduced mortality and morbidity.
4 A second study in
adults with symptomatic HIV disease showed signifi-
cantly lower morbidity in the co-trimoxazole arm.
5
These data formed the basis of a provisional recom-
mendation by the World Health Organization and the
Joint United Nations Programme on HIV/AIDS
(UNAIDS) in 2000 that co-trimoxazole should be
given to all adults and children in Africa with
symptomatic HIV-1 infection (WHO clinical stages
2, 3, and 4).
6 However, several African countries took
theviewthatitcouldnotbeassumedthatsuchabenefit
would necessarily be applicable throughout Africa.
Subsequently, a small randomised clinical trial from
Senegal was stopped early (because of the announce-
ment of the WHO/UNAIDS recommendations
6); the
authors concluded that chemoprophylaxis with low
doseco-trimoxazoledidnotshowabeneficialeffecton
survival or the occurrence of opportunistic or non-
opportunistic infections.
7 The levels of resistance of
locally relevant pathogens to co-trimoxazole was low
intheCôted’Ivoirestudies,whereasmuchhigherrates
havebeenreportedelsewhere.
8-12Zambiahasnopolicy
on co-trimoxazole prophylaxis in people with HIV
infection.
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the Zambian Ministry of Health and the University of
Zambia research and ethics committee agreed to three
randomised placebo controlled clinical trials using co-
trimoxazole prophylaxis: in children with HIV
13;i n
postnatal women with HIV; and in adults with HIV
and tuberculosis, which is reported here. Our aim was
to assess the impact of prophylactic co-trimoxazole on
reducing mortality in antiretroviral treatment naive
adults with HIV receiving treatment for newly
diagnosed active tuberculosis and in antiretroviral
naive adults with HIV who had previously received
antituberculosis treatment.
METHODS
Study setting and population
Thesettingforthestudywasthemainreferralcentrefor
tuberculosis in Lusaka, Zambia, the University Teach-
ing Hospital (UTH) chest clinic. We enrolled two
groups of HIV positive, antiretroviral naive Zambian
adults aged 16-60 years and randomised them to
receive daily co-trimoxazole or matching placebo for
the duration of the trial. The two groups were newly
diagnosed, previously untreated patients with smear
positive pulmonary tuberculosis receiving anti-
tuberculosis treatment (after one year, patients receiv-
ing a retreatment regimen were also eligible) and
clinically healthy people previously treated for tuber-
culosis but no longer receiving any treatment.
All participants had a permanent address, were not
pregnant, and were willing to give informed consent.
We excluded patients with WHO stage 4 HIV disease
who were unlikely to survive more than two weeks as
wellasthosewithahistoryofsulphonamideallergyand
those who needed treatment with or were already
receiving co-trimoxazole for other indications.
Screening, informed consent, and randomisation
All newly diagnosed, previously untreated adult
patients with smear positive pulmonary tuberculosis
seen routinely in a diagnostic clinic and patients who
had participated in an earlier trial of tuberculosis
treatment were potentially eligible. Patients were
referred to the tuberculosis chest clinic at the Uni-
versity Teaching Hospital for assessment of their
eligibility. We informed them that joining the trial
would require an HIV test, the results of which would
remain confidential. All participants received pre-test
and post-test counselling by trained counsellors. We
explained the aims and nature of the study carefully to
ensurethat participants understood that, in addition to
the standard treatment for tuberculosis, they would be
given a drug that might or might not be beneficial in
preventing other sickness often seen in patients with
tuberculosis and HIV. We also assessed potentially
eligibleparticipantsclinicallytodetermineanycontra-
indicationstoenrolment;thosewithapositiveHIVtest
resultwhofulfilledtheothercriteriaforadmissionwere
taken through the consent procedure and invited to
join the trial.
We used computer generated balanced randomised
blocks, prepared by the MRC Clinical Trials Unit
(CTU), London, to determine the randomisation
schedule. An independent member of the CTU staff
pre-labelled the trial drug. We entered names of
eligible participants on the next available line of one
of two registers(one for newly diagnosed patients, one
forpreviouslytreatedpatients)todeterminetheirstudy
numberandthedrugsupplyassignedtothem.Noneof
thestaffworkingonthetrialinZambiawasawareofthe
allocated treatment, and at no stage was it necessary to
unblind them.
Weissuedparticipantswithacontainerofstudydrug
bearing their trial number, gave them instructions
abouttakingthetrialtabletsandwhattodointheevent
of possible adverse reactions, and gave them an
appointment date four weeks later. We provided a
study identity card bearing the name of the study and
the participant’s study number. We encouraged
participants to attend whenever they were unwell and
asked them to inform the clinic if they were moving
either within or out of Lusaka.
Table 1 |Baselinecharacteristicsofstudypopulation(HIVpositivepatientsnewlydiagnosedas
having,andbeingtreatedfor,tuberculosis).Valuesarenumbers(percentages)unlessstated
otherwise
Characteristics Co-trimoxazole (n=416) Placebo (n=419)
Sex:
Male 240 (58) 226 (54)
Female 176 (42) 193 (46)
Age group (years):
15-24 47 (11) 59* (14)
25-34 210 (50) 211 (50)
35-44 127 (31) 122 (29)
≥45 32 (8) 27 (6)
Mean (SD) weight (kg)† 49.5 (7.9) 49.0 (7.2)
Mean (SD) body mass index‡ 15.5 (4.7) 15.2 (4.1)
HIV related symptoms:
Fever 195 (47) 188 (45)
Diarrhoea 22 (5) 18 (4)
Weight loss 185 (44) 197 (47)
Persistent cough 223 (54) 231 (55)
Painful genital ulceration 12 (3) 13 (3)
Herpes zoster 3 (1) 3 (1)
Generalised pruritic maculopapular rash 5 (1) 5 (1)
Oral candidiasis 16 (4) 22 (5)
Kaposi’ss a r c o m a 2( 0 . 5 ) 2( 0 . 5 )
Generalised lymphadenopathy 289 (70) 269 (64)
Other AIDS symptoms 7 (2) 9 (2)
CD4 count (cells/10
5)§:
0-49 20 (12) 25 (14)
50-99 28 (16) 22 (12)
100-199 44 (26) 53 (30)
200-299 33 (19) 32 (18)
≥300 46 (27) 45 (25)
*Includes one participant aged 14 years.
†Available for 399 co-trimoxazole and 402 placebo participants.
‡Calculated for 396 co-trimoxazole and 397 participants.
§Based on 348 (171 co-trimoxazole, 177 placebo) participants with results no more than two weeks after
randomisation.
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opportunistic infections
We randomised participants in a 1:1 ratio to receive a
supply of pre-labelled trial drug (co-trimoxazole or
matching placebo; two tablets to be taken daily). Each
co-trimoxazole tablet contained 400 mg sulfamethox-
azole and 80 mg trimethoprim.
We followed the national tuberculosis treatment
guidelinesoftheMinistryofHealthofthegovernment
of Zambia. Patients with active, previously untreated
tuberculosis received the standard regimen of etham-
butol, isoniazid, rifampicin, and pyrazinamide for two
months followed by isoniazid and ethambutol for six
months. Patients who needed re-treatment for relapse
received one of the WHO recommended retreatment
regimens.
14
If participants developed any illnesses requiring the
use of co-trimoxazole, we discontinued the study drug
and administered open label co-trimoxazole at recom-
mendedtherapeuticdoses.Thetrialdrugwasresumed
after treatment of an acute episode had been com-
pleted.
Outcomes
The primary end points were all cause mortality and
adverse events leading to an interruption of trial drug.
Follow-up
We saw participants every four weeks up to 16 weeks
and every eight weeks thereafter until the close of the
trial. We gave them four-weekly supplies of 70 trial
tablets up to and including the 12 week visit and two
four-weekly supplies at each attendance thereafter.
Patients returned unused supplies to the clinic when
attending for assessment. At each visit we recorded
informationontheantituberculosischemotherapyand
trial drug received, together with information about
visits to clinics or traditional healers or unscheduled
visits to the study clinic for illness since the previous
routine study attendance. We recorded details of
possible adverse drug effects. When necessary, parti-
cipants were admitted to hospital for investigation.
At each clinic visit, we asked participants how many
dosesofthetrialdrugtheyhadmissedandwecounted
pills. When participants failed to attend an outpatient
appointment their names were carried forward to the
next week of the diary; if they still failed to attend the
home visitor team visited the home address. If they
were absent from home or had moved to another
address we made efforts to find them, by interviewing
relatives and neighbours and visiting alternative
addresses listed in the locator form. We collected
clinical specimens for microbial analysis from partici-
pantswhoreportedillwithsymptomsandsigns.When
bacteriawerecultured,wetestedthemforsensitivityto
antibiotics.
Sample size
Assumingadeathrateof15per100personyearsinthe
previouslyuntreatedparticipants(basedonadeathrate
of18/100personyearsinatrialinasimilarpopulation
of patients in Lusaka
15), a total of 1408 person years of
observationwouldbeneededtoshowa35%reduction
indeathrateinpatientsreceivingco-trimoxazole,atthe
5% level of significance with 80% power; a 40%
reduction would require 1045 person years.
Analysis of data
We entered all data in duplicate locally and verified
thembyusingEpi-Infosoftwareversion6.04d.Master
databases were backed up at regular intervals and
copies transmitted by electronic mail to the MRC
Clinical Trials Unit in London on a monthly basis.
We set up trial management committees in London
and Lusaka to review the progress of the trial on a
regular basis and an independent data monitoring
committee to monitor the progress of the trial and
Excluded:
  HIV negative (n=617)
Excluded (n=502):
  Did not want HIV result (n=240)
  Other (n=262)
Assessed for eligibility 
Sputum positive with HIV test (n=2122)
HIV infected (n=1505)
Not on tuberculosis treatment On tuberculosis treatment*
Allocated to
placebo
(n=419)
Allocated to
co-trimoxazole
(n=416)
Allocated to
placebo
(n=84)
Allocated to
co-trimoxazole
(n=84)
Included in
survival
analysis
(n=378)
Included in
survival
analysis
(n=379)
Included in
survival
analysis
(n=84)
Included in
survival
analysis
(n=84)
No follow-up
(n=0)
No follow-up
(n=0)
No follow-up
(n=41)
No follow-up
(n=37)
Randomised (n=1003)
Fig1 | Trialprofile.*Includes73(40co-trimoxazole,33placebo)
participants who received a retreatment regimen
Table 2 |Deathratesbytuberculosisdiseasestatusandtrialdrug(HIVpositivepatientsnewly
diagnosedashaving,andbeingtreatedfor,tuberculosis)
Tuberculosis category and trial drug
Patients
assessed
Person
years Deaths
Rate (95% CI) per
100 person years
All patients receiving tuberculosis treatment:
Co-trimoxazole 416 538.3 147 27.3 (23.2 to 32.1)
Placebo 419 474.3 163 34.4 (29.5 to 40.1)
Newly diagnosed, previously untreated:
Co-trimoxazole 376 479.4 135 28.2 (23.8 to 33.3)
Placebo 386 439.8 149 33.9 (28.9 to 39.8)
Relapse/retreatment:
Co-trimoxazole 40 58.9 12 20.4 (11.6 to 35.8)
Placebo 33 34.5 14 40.6 (24.0 to 68.5)
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formal interim analyses.
WeusedtheKaplan-Meiermethod,thelogranktest,
and a Cox proportional hazard regression model to
make comparisons of the groups for the primary end
point by time to event analyses and tested hetero-
geneity of survival rates in subgroups by interaction
tests within Cox models. We fitted a fractional poly-
nomial model to assess the effect of randomised group
overtime,
16usinganearlylinearpre-transformationto
reduce the influence of outliers after a fixed time
point.
17 We made all comparisonsby intention to treat
and used Stata version 8 for analyses.
RESULTS
Participant flow
Figure 1 depicts the flow of participants during the
study. Of 1505 people who were known to be HIV
positive,240didnotwishtoreceivetheirresult;among
these, 50 people did not wish to join the trial because
theylivedtoofaraway,30reportedthattheyneededto
consultrelatives,and19thoughtthattheirbloodwould
be used for satanic purposes; 115 gave no reason.
Study population
Between June 2000 and January 2004, we randomised
1003 patients. Of these, 835 (416 co-trimoxazole, 419
placebo) were receiving treatment for tuberculosis, of
whom 762 (376 co-trimoxazole, 386 placebo) were
newly diagnosed previously untreated patients and 73
(40 co-trimoxazole, 33 placebo) were receiving a
retreatment regimen; 168 (84 co-trimoxazole, 84
placebo) were not on treatment but had received
treatmentinthepast.ThetrialwasclosedinSeptember
2004, when funding for antiretroviral treatment
became available for those participants who were
eligible. Follow-up from the time of randomisation
ranged from 0 to 46 months. A total of 1012.6 person
years of data were accumulated from participants
receiving treatment for tuberculosis at the time of
randomisation (919.2 from newly diagnosed pre-
viously untreated patients and 93.4 from those being
retreated for relapse) and 457.5 person years from
those not on treatment. The main analyses are
restricted to patients receiving antituberculosis treat-
ment.
Baseline data
Table 1 shows the baseline characteristics of the
participantsreceivingantituberculosistreatmentatthe
time of randomisation. Most (56%) were men, with an
averageageof32.7(SD7.5)years;themeanweightwas
49.3 (SD 7.6) kg, and the mean body mass index was
15.3 (SD 4.4). A total of 762 participants were newly
diagnosed, previously untreated patients, and 73
(8.7%) were receiving retreatment regimens. Apart
from symptoms associated with tuberculosis, only a
smallnumberofparticipantshadsymptomsassociated
with HIV/AIDS. Only 348 (42%) of the participants
had CD4 counts (measured no later than two weeks
afterthestartoftrialdrug);55%ofthesehadcountsless
than200cells/μl.Thetwogroupswerebroadlysimilar
in their characteristics.
Follow-up
We had no information on 78 (37 co-trimoxazole, 41
placebo) (9.3%) participants after randomisation.
Follow-up rates were slightly higher in the co-
trimoxazole arm than in the placebo arm throughout
the study. The proportion seen or known to have died
remained at 80% or more throughout the study; for
example, 80% of 387 participants expected at
24 months and 83% of 266 participants expected at
30 months were assessable. During follow-up, partici-
pants in the co-trimoxazole group received trial drug
during 82.9% of their time at risk and those in the
placebo group received trial drug 81.0% of that time.
Ofthoseparticipantsseenat follow-up,269/379(71%)
in the co-trimoxazole group and 259/378 (69%) in the
placebogroupspent80%ormoreoftheirtimesupplied
with trial drug; the corresponding proportions who
spent 90% or more of their time supplied with drug
were 204/379 (54%) and 201/378 (53%).
Outcomes and death rates in patients on tuberculosis
treatment
A total of 310 patients died during the course of the
study;thedeathrateswere27.3per100personyearsin
participants treated with co-trimoxazole and 34.4 per
100personyearsinthosetreatedwithplacebo(table 2).
Co-trimoxazolewasassociatedwitha21%reductionin
all cause mortality (hazard ratio 0.79, 95% confidence
interval 0.63 to 0.99; P=0.04). The number needed to
treat to prevent one death was 141.8 (95% confidence
interval 71.7 to 588.7). Figure 2 shows the Kaplan-
Meier plots of time to death for all 835 patients. The
figure suggests a delay before any benefit from co-
trimoxazole becomes evident (see exploratory ana-
lyses below). We sawbenefit in bothnewly diagnosed,
previously untreated participants and in those being
treated for relapse. Analysis by CD4 count on the
subset of participants with data available showed no
evidence of difference in benefit according to the level
of immunosuppression (P>0.5, test for heterogeneity);
we saw no difference in benefit by age or sex.
Ancillary and exploratory analyses
We explored possible changes in the effect of co-
trimoxazole over a prolonged period of time by
dividing time after randomisation into four segments
Table3 |Changeovertimesincerandomisationinpossiblebenefitfromco-trimoxazoleovertimein
HIVpositivepatientsnewlydiagnosedashaving,andbeingtreatedfor,tuberculosis
Time period Patients assessed Person years Hazard ratio (95% CI) P value
All follow-up 762 919.2 0.83 (0.65 to 1.05) 0.09
0-6 months 762 315.9 1.24 (0.81 to1.88) 0.3
6-12 months 546 225.4 0.55 (0.34 to 0.86) 0.009
12-18 months 370 155.2 0.55 (0.31 to 099) 0.05
≥18 months 261 222.6 1.05 (0.65 to1.70) 0.8
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analysis of newly diagnosed, previously untreated
patients. We found significant differences in the
different time periods (P=0.02, test for heterogeneity),
withnoevidenceofbenefitinthefirstsix monthsbuta
consistent benefit between six and 18 months asso-
ciatedwitha45%reductioninmortalityinparticipants
receiving co-trimoxazole (table 3). From 18 months
onwards, no further benefit was apparent. Fitting a
fractionalpolynomialtotheeffectofrandomisedgroup
over time and shrinking the effect of outliers beyond
three years confirmed these results, although the
confidence limits were wide.
Unplanned analyses suggested that benefit from co-
trimoxazolewasassociatedwiththeproportionoftime
at risk for which participants were in receipt of trial
drug.Thus,forthosespending90%ormore,75%-90%,
orlessthan75%oftheirtimesuppliedwithstudydrug,
the hazard ratios were 0.65 (0.45 to 0.93), 0.68 (0.40 to
1.18), and 1.24 (0.88 to 1.73).
Attendance at other clinics
Of the 729 (362 co-trimoxazole, 367 placebo) patients
who attended at least one of the follow-up clinics, 61
(17%) co-trimoxazole participants (111 additional
visits) and 92 (25%) placebo participants (155 addi-
tionalvisits)reportedhavingvisitedanothercliniconat
least one occasion between follow-up visits (P=0.006).
Adverse events leading to planned interruption of trial
drug
Suspected adverse events leading to a planned inter-
ruption of trial drug occurred in 18 patients (12 co-
trimoxazole, 6 placebo); all except six (all co-trimox-
azole) resumed the trial drug. The reactions leading to
permanent discontinuation were Stevens Johnson
syndrome and anaemia, itchy rash, swollen face and
lips, peripheral neuropathy, and two cases of anaemia.
Death rates in previously treated patients not on
t r e a t m e n ta tt i m eo fe n r o l m e n t
The death rates in the 168 patients who had received
treatment for tuberculosis in the past but were not on
treatment at the time of enrolment were 14.5 (95%
confidence interval 10.3 to 20.5) per 100 person years
intheplaceboarmand14.7(10.5to20.6)per100inthe
co-trimoxazole arm.
DISCUSSION
ThisstudyconfirmstheresultsofthetrialdoneinCôte
d’Ivoire and the subsequent observational studies, in
showingthat prophylaxiswithco-trimoxazolereduces
mortality in adults with HIV infection who have
pulmonary tuberculosis and that co-trimoxazole was
generally safe and well tolerated. This is the only
placebo controlled randomised clinical trial of co-
trimoxazole prophylaxis that we are aware of in HIV
positive adults with active tuberculosis since those
done in Côte d’Ivoire and Senegal.
47
Review of non-randomised studies
Several non-randomised studies have been reported
from central and southern Africa.
18-21 A comparisonof
more than 3000 patients in the Hlabisa subdistrict of
northern KwaZulu-Natal reported a 29% reduction in
mortality at six months when all patients with
tuberculosis, irrespective of their HIV status, were
given co-trimoxazole compared with a historical
cohort receiving no prophylaxis.
18 Zachariah and
colleagues did a study in a rural district in Malawi, in
which all patients with tuberculosis were offered
voluntary counselling and HIV testing and those
found to have HIV infection were offered co-trimox-
azole adjunctive to their tuberculosis treatment.
19 The
relativeriskofdeathwithin12monthswasdecreasedin
those receiving co-trimoxazole (adjusted hazard ratio
0.81, 95% confidence interval 0.75 to 0.87) compared
with a historical cohort. In a study in the Karonga
district of Malawi, 18 month survival rates were
compared between HIV positive patients with tuber-
culosisregisteredin1999andthoseregisteredin2000,
who were offered co-trimoxazole.
20 The hazard ratio
for death for the period 3-18 months was 0.67 (0.45 to
1.00). In Uganda, co-trimoxazole was offered to a
cohort of HIV positive people, and decreased mortal-
ity and morbidity were reported compared with
historical controls who had not received co-
trimoxazole.
21 These studies have several potential
limitations. As with any historical comparison, being
certain that the populations were comparable in their
characteristics or that levels of care did not improve
overtimeisdifficult.Theextenttowhichmortalitywas
ascertained may also have varied.
Reduction in mortality risk
Overall, the reduction in risk found in our study was
less than has been reported elsewhere. Retrospective
exploratory analyses in the newly diagnosed patients
indicate a lack of benefit during the first six months,
coincidinginpartwiththeadministrationofrifampicin
(which has a broad spectrum of activity against a
variety of bacterial infections) in the initial two month
Time (years)
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0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
0
0.4
0.6
0.8
0.2
Co-trimoxazole
Log rank
χ 2=4.12
P=0.04
Placebo
Co-trimoxazole
At risk:
416 219 108 33
Placebo 419 190 79 17
Fig 2 | Time to death according to trial drug (based on 835 HIV
positivepatientsnewlydiagnosedashaving,andbeingtreated
for, tuberculosis)
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apy.Afterthiscameaperiodofabout12monthsduring
which we saw a significant reduction in mortality of
45%,verysimilartothosereportedintheCoted’Ivoire
trial and the CHAP trial of HIV positive children in
Zambia.
413 These results should be interpreted with
caution, as they are based on unplanned subgroup
analyseswithrelativelysmallnumbersofpersonyears.
However, the benefit seems to wane in the long term,
possibly owing to a fall in adherence levels, develop-
ment of resistance to co-trimoxazole, or death from
causes not prevented by co-trimoxazole. An analysis
according to time in receipt of study drug showed a
significant benefit in patients who collected co-
trimoxazole regularly.
Implementation of co-trimoxazole prophylaxis
The risks of increasing levels of bacterial resistance to
co-trimoxazole and possibly increasing resistance to the
antimalarialdrugFansidar(pyrimethamine-sulfadoxine)
needtobeassessedinthelightofanybenefitfromgiving
co-trimoxazole. In vitro studies indicate cross resistance
betweensulfamethoxazoleandsulfadoxineandbetween
trimethoprim and pyrimethamine,
22 so implementation
of co-trimoxazole prophylaxis in areas where malaria
and HIV overlap might result in selection for antifolate
resistantmalaria.Selectionforresistantmalariaparasites
could occur within patients infected with malaria and
taking co-trimoxazole prophylaxis, putting them at
increased risk of treatment failure.
2324 However, global
policyrecommendationsforthe use of co-artemetheras
prophylaxis for malaria are being increasingly imple-
mented, and this concern may become less relevant.
The routine use of co-trimoxazole in developing
countries,especiallysub-SaharanAfrica,hasbeenslow
to beimplementeddespite the provisionalrecommen-
dations from WHO and UNAIDS in 2000 that co-
trimoxazoleshouldbegiventoeveryoneinAfricawith
HIV/AIDS, including those who have tuberculosis.
The effects of current efforts to introduce highly active
antiretroviral treatment into health systems in Africa
will not be fully evaluated until its use is more
widespread
25; it may have substantial potential to
prevent fatal infections. Collaboration between
national programmes on tuberculosis and HIV is
becomingessentialinoptimisingthejointmanagement
of tuberculosis and HIV/AIDS in highly endemic
areas,makingco-trimoxazoleprophylaxisincreasingly
available.
Our findings now provide a strengthened evidence
base for the UNAIDS /WHO guidelines issued in
2000.
6 The WHO Department of HIV/AIDS has
recentlyrevisedtheinterimUNAIDS/WHOpolicyon
use of co-trimoxazole in people living with HIV/
AIDS.
26 Analysis by CD4 counts on the subset of
participants with data available showed no differences
in benefit according to level of immunosuppression.
LimiteddataonCD4countssuggestnoclear evidence
as to when to start co-trimoxazole. The optimal timing
of co-trimoxazole prophylaxis has yet to be deter-
mined.
After an experts’ consultation meeting in Geneva in
February2005,WHOidentifiedfourpriorityareasfor
research into co-trimoxazole prophylaxis.
27 These
were the role of co-trimoxazole prophylaxis in the
context of concomitant antiretroviral treatment in
Africa, defining the optimal timing of co-trimoxazole
prophylaxisamongHIVpositivepeoplewithtubercu-
losis, defining the determinants that influence the
efficacy of co-trimoxazole prophylaxis, and determin-
ingthebestdeliverystrategiestoimprovetheuptakeof
co-trimoxazole prophylaxis.
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